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Abstract
Background: Antenatal immunization of mothers with influenza vaccine increases serum antibodies and reduces the rates
of influenza illness in mothers and their infants. We report the effect of antenatal immunization on the levels of specific anti-
influenza IgA levels in human breast milk. (ClinicalTrials.gov identifier NCT00142389; http://clinicaltrials.gov/ct2/show/
NCT00142389).
Methods and Findings: The Mother’s Gift study was a prospective, blinded, randomized controlled trial that assigned 340
pregnant Bangladeshi mothers to receive either trivalent inactivated influenza vaccine, or 23-valent pneumococcal
polysaccharide vaccine during the third trimester. We evaluated breast milk at birth, 6 weeks, 6 months, and 12 months,
and serum at 10 weeks and 12 months. Milk and serum specimens from 57 subjects were assayed for specific IgA antibody
to influenza A/New Caledonia (H1N1) using an enzyme-linked immunosorbent assay (ELISA) and a virus neutralization assay,
and for total IgA using ELISA. Influenza-specific IgA levels in breast milk were significantly higher in influenza vaccinees than
in pneumococcal controls for at least 6 months postpartum (p= 0.04). Geometric mean concentrations ranged from 8.0 to
91.1 ELISA units/ml in vaccinees, versus 2.3 to 13.7 ELISA units/mL in controls. Virus neutralization titers in milk were 1.2 to 3
fold greater in vaccinees, and correlated with influenza-specific IgA levels (r = 0.86). Greater exclusivity of breastfeeding in
the first 6 months of life significantly decreased the expected number of respiratory illness with fever episodes in infants of
influenza-vaccinated mothers (p= 0.0042) but not in infants of pneumococcal-vaccinated mothers (p= 0.4154).
Conclusions: The sustained high levels of actively produced anti-influenza IgA in breast milk and the decreased infant
episodes of respiratory illness with fever suggest that breastfeeding may provide local mucosal protection for the infant for
at least 6 months. Studies are needed to determine the cellular and immunologic mechanisms of breast milk-mediated
protection after antepartum immunization.
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Introduction
Young infants (0–6 months of age) throughout the world
experience high rates of influenza infection, clinic visits, and
hospitalization [1–6]. In some winters, as many as nine percent of
all infants less than 6 months of age experience an influenza-
related illness and require care in a clinic, emergency room or
hospital ward [2]. Hospitalization rates for infants 0 to 6 months of
age in the United States range from 45 to 104 per 10,000 infants.
Of U.S. children less than age five who are hospitalized for
influenza, 48% are infants less than 6 months of age [2,6].
Despite the demonstrated burden of influenza illness, influenza
immunization is not licensed for infants less than 6 months of age
by the U.S. Federal Drug Administration. Oseltamivir was
approved for use in infants greater than 2 weeks of age in
December 2012. Few studies have been done to assess the safety
and immunogenicity of influenza immunization in infants before
6 months of age [7,8]. These studies suggest that influenza
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immunization in this age group produces low seroresponses, in
part due to presence of passive maternal antibody [7,8]. With
limited prevention and treatment strategies, alternate approaches,
including maternal immunization, are needed to protect infants
from influenza during the 0 to 6 month period of high
vulnerability.
Maternal antenatal immunization produces substantial levels of
maternal and infant serum IgG [9], but we are not aware of
reports describing the effect of antenatal immunization on specific
anti-influenza IgA levels in human breast milk during prolonged
lactation. Non-randomized observational studies suggest that
breastfeeding is associated with protection against all respiratory
disease [10], though data are limited with regard to specific
influenza protection. A recent study in Argentina demonstrated
that breastfeeding is associated with type I interferon production in
infants infected with influenza virus [11]. A report of unvaccinated
women from Bulgaria in 1994 used hemagglutination inhibition
(HAI) assays to show that the presence of influenza antibody levels
are somewhat higher in breast milk than in serum [12]. There
have been studies in guinea pig milk [13] demonstrating protection
of the pups when the mothers were immunized antepartum, as
well as studies in humans describing breast milk antibody
production for other microorganisms [14,15].
Several studies have demonstrated that influenza immunization
of mothers protects both mothers and young infants [16–19]. A
unique randomized controlled trial of antenatal maternal immu-
nization in Dhaka, Bangladesh demonstrated a 63 percent
reduction in laboratory-proven influenza illness among infants
born to influenza vaccinated mothers [19]. This clinical effective-
ness was observed in infants up to 6 months of age, despite a
steady decline in infant passive influenza serum IgG antibody after
delivery resulting in very low levels at 5 to 6 months [9]. A
retrospective study from the Navajo and White Mountain Apache
Indian reservations in Southwest United States demonstrated a 41
percent reduction in the risk of laboratory-proven influenza
infection for infants born to influenza-vaccinated women [16].
This study similarly showed a steady decline of passively acquired
maternal anti-influenza antibody levels in infant serum [16].
Recent retrospective reports of antenatal influenza immunization
from the New Vaccine Surveillance Network and from the
northeastern United States show vaccine-associated reductions of
laboratory-confirmed, influenza-associated hospitalization in less
than 6 month old infants ranging from 45 to 92 percent,
respectively [17,18].
The steady decline in passively acquired infant serum anti-
influenza IgG antibodies is in contrast with evidence of clinical
protection of infants against influenza up to 6 months post-
delivery. We hypothesize that specific anti-influenza IgA antibod-
ies in breast milk may be sustained for 6 to 12 months post-
delivery, potentially providing local mucosal protection for the
infant during this time period. Our aim was to assess breast milk
anti-influenza IgA antibody and virus neutralizing activity in
influenza vaccine recipients and control mothers during
12 months of observation, and we demonstrated sustained levels
of specific anti-influenza IgA in milk and decreased infant
respiratory illness with fever for at least 6 months postpartum.
Methods
Ethics statement
The project protocol was reviewed and approved by the Ethical
Review Committee at the International Centre for Diarrheal
Disease Research, Bangladesh, the Institutional Review Board at
the Bloomberg School of Public Health at Johns Hopkins
University, Baltimore, and the Institutional Review Board at
Cincinnati Children’s Hospital Medical Center in Cincinnati,
Ohio. Use of study vaccines was approved by the Directorate of
Drug Administration, the Government of the People’s Republic of
Bangladesh.
Study design and participants
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The design, clinical methods and statistical analyses
have been described for a prospective, individually randomized,
double-blinded, parallel group trial (ClinicalTrials.gov number,
NCT00142389, http://clinicaltrials.gov/show/NCT00142389),
called the Mother’sGift Study. This study assessed the safety and
immunogenicity of pneumococcal vaccines, as well as the clinical
effectiveness of influenza vaccine, in Bangladeshi women and their
infants followed for one year from delivery after immunization
during the third trimester with either inactivated trivalent
influenza vaccine or 23-valent pneumococcal polysaccharide
(23vPPS) vaccine (control) [19]. We conducted a pre-specified
secondary analysis to assess the concentration and duration of
breast milk anti-influenza IgA antibody in mothers who received
influenza vaccine during third trimester compared to control
group mothers (Figure 1).
Briefly, mothers were recruited for the Mother’sGift study [19]
at three clinics in Dhaka, Bangladesh, during the third trimester of
pregnancy. After obtaining written informed consent, we random-
ly assigned 340 pregnant women aged 18–36 to receive either
influenza or 23vPPS vaccine during the third trimester of
pregnancy. Mothers reported breastfeeding frequency, along with
frequency of other infant foods and episodes of infant respiratory
illness with fever, every week for the first 6 months of life.
Randomization and masking
The randomization sequence was computer-generated, strati-
fied according to clinic, and blocked in groups of four; sequentially
numbered opaque envelopes with data regarding assignments to
study groups were provided to each clinic. Mothers, families, and
study staff who collected data were unaware of the study-group
assignments. Clinic staff members who were not involved with
study-outcome assessments administered all doses of vaccine.
Study Vaccines
Mothers were randomly assigned to receive the inactivated
influenza virus vaccine, FluarixH, containing the WHO recom-
mended influenza antigens for the southern hemisphere in 2004:
A/New Caledonia (H1N1), A/Fujian (H3N2), and B/Hong Kong
(lot number, AFLUA004BC; GlaxoSmithKline Biologicals), or the
23vPPS vaccine, PneumovaxH (lot number, 0987N; Merck & Co.,
Inc.). All study vaccines were purchased from the manufacturer.
The FluarixH was given intramuscularly with a 1.5 centimeter
needle, while the PneumovaxH was given subcutaneously with a
0.5 centimeter insulin syringe.
Antibody Assays
Breast milk samples were collected by hand expression by all
participants at delivery, and at 6, 10, 14, 18 weeks, and 6 and
12 months post-delivery. Maternal serum was obtained at
10 weeks and 12 months post-partum. For this analysis, we
evaluated breast milk at birth, 6 weeks, 6 months, and 12 months,
and maternal serum at 10 weeks and 12 months. The milk whey
was separated and frozen at minus 70u Celsius. Specimens were
transported to Cincinnati Children’s Hospital Medical Center,
Antibodies to Influenza Virus in Human Milk
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where breast milk and serum from 57 subjects were evaluated for
IgA specific for influenza A/New Caledonia (H1N1) antigen using
an enzyme-linked immunosorbent assay (ELISA). Briefly, the
ELISA was performed by coating plates with 0.75 mg/ml of
baculovirus-expressed recombinant hemagglutinin derived from
the A/New Caledonia/20/99 (H1N1) strain (BEVS rHA, Protein
Sciences Corporation, Meriden CT). After an overnight incuba-
tion, ELISA plates were washed with PBS +0.05% Tween 20 and
blocked with 0.89% BSA solution (Bovine Serum Albumin
Fraction V 7.5% solution, Gibco-Invitrogen, Carlsbad, CA) in
1% non-fat dry milk (Carnation Nonfat Dry Milk, Nestle Food
Company, Vevey, Switzerland). A human serum reference
standard serially diluted to generate a reference curve and samples
diluted at 1:20 and 1:200 were added to duplicate wells on each
plate. The plates were incubated, washed and biotinylated rabbit-
anti human IgA (Jackson ImmunoResearch Laboratories, West
Grove, PA) was added. After incubation, the plates were washed
and peroxidase conjugated avidin-biotin solution (Vector PK4000
Kit, Vector Laboratories, Burlingame, CA) was added. After
incubation and final washing the substrate, O-phenylenediamine,
dihydrochloride solution (OPD 15 mg tablet, Sigma Aldrich, St.
Louis, MO) was added and incubated. The colorimetric reaction
was stopped by adding 1 M sulfuric acid and the plates were read
at a wavelength of 490 nm. The concentration of influenza-
specific IgA was derived by extrapolation from the standard curve
generated from the reference serum with the assigned quantity of
anti-influenza IgA expressed in ELISA units/mL (EU). Samples
below the limit of detection (0.04 EU) were assigned a value of
,0.04. Samples that were above the limit of the standard curve
were repeated at a higher dilution to obtain a reportable value.
We also performed a total IgA EIA assay that was similar to the
above assay except that plates were coated with Rabbit anti-
human IgA, and a purified human IgA (Sigma Aldrich, St. Louis,
MO) was used as a standard. A serum neutralization assay for
influenza A/New Caledonia (H1N1) on the 57 milk samples was
performed, using a method previously described by Rowe et al
[20] with some modifications. Using an extrapolation method
created in SoftMax Version 5.3, the OD values of the dilution
series of each sample was modeled using a five parameter logistic
regression function. For each fitted curve, the dilution which
corresponds to a 50% response is extrapolated. This value
represents the titer of the serum against a given virus, which
represents a 50% reduction in amount of virus.
Statistical Analysis
The numbers of subjects that were needed for the primary study
were calculated to detect a specified difference in mean
pneumococcal antibody titer in the two groups [19]. A comparison
of characteristics of mothers in this report was done. Continuous
variables were summarized as mean and standard deviation and
differences between groups were tested with a two-sample T-test.
Categorical variables were compared across groups using a chi-
squared test of independence. We calculated geometric mean
concentrations (GMC) of anti-influenza IgA antibodies in breast
milk, and of neutralizing titers for subjects at four time points.
Differences between vaccine groups in log-transformed IgA titers
were tested using a repeated measures analysis of variance. Due to
the correlation among outcome measures in each family of
comparisons, we used the Bonferroni method to adjust for multiple
comparisons. Since breast milk composition, including total IgA, is
known to vary by time of day, by time since last feeding, and
Figure 1. CONSORT study diagram. Of the 340 women randomized to receive influenza vaccine or pneumococcal vaccine, breast milk samples
from 57 women were analyzed for IgA antibody and neutralizing activity.
doi:10.1371/journal.pone.0070867.g001
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during the feeding, we adjusted the specific IgA levels in each milk
specimen by dividing specific IgA levels by total IgA to obtain an
adjusted specific IgA level. This increased the likelihood that
changes in influenza-specific IgA were secondary to type of
vaccine received rather than routine variations in breast milk
composition. In the breast milk analysis, the response variables for
the repeated measures ANOVA models were antigen-specific IgA
in breast milk, total IgA in breast milk, neutralization titers in
breast milk, and adjusted specific IgA, while independent variables
were maternal vaccine group and postpartum time. In the serum
analysis, the response variables for the repeated measures
ANOVA models were antigen-specific IgA and neutralization
titers in serum, while independent variables were maternal vaccine
group and time. We also calculated ratios of neutralization to IgA
titers in milk and serum in vaccine and controls. In order to test
the effect of breast milk on infants born to the 57 influenza- and
pneumococcal- vaccinated mothers, we analyzed the effect of
maternal vaccine and exclusivity of breastfeeding on infant
episodes of respiratory illness with fever. We calculated a
breastfeeding score as an average measure of exclusive breastfeed-
ing for the first 6 months of life. Weeks of exclusive breastfeeding
were given a score of 1, partial breastfeeding 0.5, and no
breastfeeding 0. We then averaged the score over all weeks. We
conducted a stratified Poisson regression analysis modeling the
number of respiratory illness episodes in the first 6 months of life
in each of the two vaccine groups.
Results
Of 340 women enrolled in the study, 172 women received
influenza vaccine and 168 received 23-valent pneumococcal
capsular polysaccharide vaccine, of which 30 and 27, respectively,
had both breast milk and serum available over 12 months for
analysis. Differences between vaccine groups were non-significant
for maternal age, birth length, birth weight, gestational weeks,
maternal education, maternal height, Apgar scores, gravidity,
parity, breastfeeding score, delivery type, and infant sex (Table 1).
Differences were statistically significant for interval from vaccina-
tion to delivery, with mothers who received pneumococcal vaccine
experiencing a 13 day longer interval than mothers who received
influenza vaccine. Additionally, place of delivery was significantly
different between groups, with mothers who received influenza
vaccine delivering more frequently at a hospital (Table 1).
Influenza-specific IgA and neutralization antibody in
breast milk
Mean anti-influenza IgA antibody was higher in milk of the
mothers who received influenza vaccine, with the highest levels at
delivery (Table 2). After adjustment for multiple comparisons,
anti-influenza IgA was significantly higher in influenza vaccinees
at delivery, 6 weeks, and 6 months, but similar between groups at
12 months. In contrast, total IgA in breast milk was similar
between vaccine groups at all four time points and dropped
steadily over the study period. Neutralization titers were signifi-
cantly higher in influenza vaccinees at the time of delivery but
Table 1. Maternal and infant characteristics by vaccine group.
VACCINE
Variable Influenza (n=30) Control (n = 27) p value*
Maternal Age (years) 24.2764.20 24.7063.71 0.68
Birth length (centimeters) 49.5261.81 49.1562.02 0.46
Birth weight (kilograms) 3.0460.38 3.1460.52 0.39
Gestational weeks 39.1761.32 39.4861.34 0.38
Maternal Education (years) 11.3363.23 11.4462.82 0.89
Mother’s height (centimeters) 152.8864.68 153.3365.69 0.75
Apgar at 1 minute 8.0760.83 8.2660.53 0.31
Apgar at 5 minutes 9.3360.66 9.3760.49 0.81
Gravidity 1.8061.10 2.0461.13 0.42
Parity 0.9360.83+ 1.1360.72++ 0.49
Breast feeding score (1 = 6 months of exclusive breast milk) 0.8160.16 0.8560.14 0.35
Days from vaccination to delivery 51.27613.11 64.89615.11 0.0006
Place of Delivery 0.02
Clinic 19 (63.33%) 24 (88.89%)
Hospital 11 (36.67%) 3 (11.11%)
Delivery Type 0.52
Normal 11 (36.67%) 8 (29.63%)
Episiotomy 9 (30.00%) 6 (22.22%)
Caesarean 10 (33.33%) 13 (48.15%)
Infant Sex 0.44
Male 17 (56.67%) 18 (66.67%)
Female 13 (43.33%) 9 (33.33%)
*p values were calculated using a T test for all variables except Place of Delivery, Delivery Type, and Infant Sex (Chi Squared). + N= 14++ N= 16.
doi:10.1371/journal.pone.0070867.t001
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Figure 2. Geometric mean adjusted influenza-specific IgA in breast milk in influenza versus control vaccines. Geometric mean
adjusted influenza-specific IgA antibody is significantly higher in the breast milk of influenza vaccinees compared to control vaccinees for at least
6 months postpartum.
doi:10.1371/journal.pone.0070867.g002
Table 2. Breast milk IgA antibodies and influenza virus neutralization titers in influenza and control vaccines.
Influenza vaccine Control vaccine
Time postpartum Assay N GMC (95% CI) N GMC (95% CI) p value
Bonferroni
Adjusted p
value
Influenza/Control
vaccine ratio
0 days Influenza Specific IgA (EU/mL) 29 91.1 (48.6–170.8) 27 13.7 (7.8–24.3) ,0.0001 ,0.0001 6.64
Total IgA (EU/mL) 29 2989.8 (2189.8–
4082.2)
27 2778.0 (1884.1–
4095.9)
0.66 1 1.08
Adjusted Specific IgA 29 3.1 (1.8–5.3) 27 0.5 (0.3–0.7) ,0.0001 ,.0001 6.17
Neutralization Titer 28 186.5 (121.2–286.9) 27 63.7 (43.6–93.0) ,0.0001 0.001 2.93
6 weeks Influenza Specific IgA (EU/mL) 30 9.6 (5.6–16.6) 27 2.3 (1.5–3.4) 0.0002 0.005 4.26
Total IgA (EU/mL) 30 474.7 (416.7–540.9) 27 464.3 (401.9–536.4) 0.89 1 1.02
Adjusted Specific IgA 30 2.0(1.2–3.5) 27 0. 5 (0.3–0.7) ,0.0001 0.001 4.16
Neutralization Titer 30 19.4 (14.3–26.2) 26 12.1 (10.4–14.2) 0.07 1 1.60
6 months Influenza Specific IgA (EU/mL) 30 8.0 (4.2–15.0) 27 2.3 (1.6–3.5) 0.001 0.04 3.43
Total IgA (EU/mL) 30 483.0 (386.4–603.7) 26 472.1 (410.6–542.7) 0.89 1 1.02
Adjusted Specific IgA 30 1.7(1.0–2.8) 26 0. 5 (0.4–0.8) 0.001 0.03 3.12
Neutralization Titer 29 18.6 (12.3–28.1) 27 15.9 (10.5–24.2) 0.55 1 1.17
12 months Influenza Specific IgA (EU/mL) 30 11.1 (6.0–20.7) 27 4.3 (2.6–7.0) 0.01 0.34 2.61
Total IgA (EU/mL) 30 711.7 (557.0–909.3) 27 716.2 (561.4–913.7) 0.97 1 0.99
Adjusted Specific IgA 30 1.6 (0.9–2.7) 27 0. 6(0.4–0.9) 0.005 0.13 2.63
Neutralization Titer 28 19.7 (12.9–30.1) 27 15.5 (10.7–22.3) 0.35 1 1.27
Abbreviations: N, number; CI, confidence interval; GMC, geometric mean concentration.
doi:10.1371/journal.pone.0070867.t002
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were not significantly different between groups at 6 weeks,
6 months, and 12 months postpartum. Adjusted specific IgA
levels (Figure 2) were significantly greater in the influenza vaccine
group and remained significantly greater for 6 months. The
GMCs for specific anti-influenza IgA antibody in milk over all
time points were 16.9 and 4.19 EU/ml in vaccinees and controls,
respectively (p,0.0001). There was no significant statistical
interaction between vaccine and time, meaning that the rate of
decrease in serum or milk antibody was similar between study
groups.
Influenza-specific IgA and neutralization antibody in
serum
Influenza-specific serum IgA levels and neutralization antibod-
ies were higher in the mothers who received influenza vaccine,
with the highest levels at delivery (Table 3). The influenza-specific
IgA levels were statistically similar by 12 months postpartum.
Neutralization antibodies were statistically different between
groups at delivery (Figure 3), but titers were similar at 12 months
postpartum after adjustment for multiple comparisons (al-
pha= 0.16). There was no significant interaction between vaccine
and post-natal time, meaning that the rate of decrease in anti-
influenza IgA antibody was similar between study groups.
Figure 3. Geometric mean neutralization titers in serum in influenza versus control vaccines. Geometric mean anti-influenza
neutralization titers are significantly higher in the serum of influenza vaccinees compared to control vaccinees at delivery.
doi:10.1371/journal.pone.0070867.g003
Table 3. GMCs of serum influenza specific IgA antibody and influenza virus neutralization titers in influenza and control vaccines.
Influenza vaccine Control vaccine
Time postpartumAssay N GMC (95% CI) N GMC (95% CI) p value
Bonferroni
Adjusted p
value
Influenza/Control vaccine
ratio
0 days Influenza Specific IgA
(EU/mL)
30 29.2 (14.4–59.2) 26 9.2 (5.8–14.5) 0.01 0.04 3.12
Neutralization Titer 30 2773.6 (1772.6–4339.9) 26 711.5 (493.7–
1025.3)
,0.0001 ,0.0001 3.88
12 months Influenza Specific IgA
(EU/mL)
28 235 (11.2–49.4) 26 10.3 (6.8–15.8) 0.06 0.35 2.25
Neutralization titer 28 1046.4 (695.4–1574.6) 26 561.0 (401.0–
784.8)
0.03 0.16 1.81
Abbreviations: N, number; CI, confidence interval; GMC, geometric mean concentration.
doi:10.1371/journal.pone.0070867.t003
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Breastfeeding and infant episodes of respiratory illness
with fever
Greater exclusivity of breast feeding in the first 6 months of life
significantly decreased the estimated number of respiratory illness
with fever episodes in infants of influenza-vaccinated mothers
(p=0.0042) but not in infants of pneumococcal-vaccinated
mothers (p=0.4154).
Discussion
Our study examined breast milk and serum anti-influenza IgA
antibody concentrations during the postpartum year after immu-
nization of pregnant Bangladeshi women with either influenza or a
control vaccine. To our knowledge, this is the first report of the
levels and changes in human milk of specific anti-influenza IgA
and of virus neutralization activity after antenatal influenza
immunization. Mean breast milk antibody levels were significantly
higher at delivery in mothers who received influenza vaccine and
declined by six weeks, as has been described for other antigens
[14,15,21,22]. However, milk IgA concentrations specific for the
seasonal A/New Caledonia (H1N1) antigen were statistically
significantly higher in influenza vaccinees as long as 6 months
postpartum. The higher levels of specific IgA and of adjusted
specific IgA in influenza vaccinees through 6 months suggest
active specific antibody production throughout lactation. This is
further supported by the significantly decreased number of
respiratory illness with fever episodes observed in infants of
influenza-vaccinated mothers. We noted that the breast milk anti-
influenza IgA GMCs in the vaccine and the control group
increased between 6 months and 12 months postpartum, suggest-
ing maternal natural antigenic stimulation from seasonal influenza
in both groups. Total milk IgA concentrations were similar
between vaccine groups and decreased by six weeks of age.
However, adjusted anti-influenza specific milk IgA was statistically
different for at least 6 months. Interestingly, postpartum time was
not a significant predictor of adjusted specific anti-influenza milk
IgA, meaning that the influenza-specific IgA was 2.6 to 6.6 times
higher in influenza-immunized mothers for 6 months.
Our study had several potential limitations. The sample size was
small, limiting our power to detect differences. We were unable to
include a control group of women who were not breastfeeding,
due to the difficulty of obtaining breast milk beyond the immediate
postpartum period. Data from this South Asian setting may have
limited generalizability to other regions with variations in
influenza seasonality and exposure, and in maternal and infant
nutritional status. We assessed immune responses to only a single
antigen of the trivalent influenza vaccine, but patterns of sustained
IgA milk antibody production are likely to be seen with other
vaccine antigens [21,22]. Previous analyses of serum HAI titers
suggest a difference in antibody response and placental transfer of
antibody by antigen [9].
The sustained high levels of specific IgA in breast milk of
women immunized during pregnancy suggest that breastfeeding
may provide vaccine-specific local mucosal protection for the
infant up to 6 months of age [23,24]. Secretory IgA is the most
abundant immunoglobulin in breast milk, with concentrations of
1–2 g/L early in lactation [25]. It is secreted as a dimer linked via
a secretory chain, conferring resistance against intestinal proteol-
ysis [25]. We know from previous studies in women with vaccines
against pertussis [26], rotavirus [27], and measles [28] that
secretory IgA is produced in the breast milk in response to these
vaccines. We are not aware of previous research documenting the
production of specific anti-influenza IgA in breast milk after
immunization. We are undertaking studies to determine the
cellular and immunologic mechanisms of breast milk-mediated
protection after antepartum immunization. These findings need
replication, including with other vaccines like diphtheria, tetanus,
and pertussis vaccine, but suggest that pregnant mothers should be
aware of the infant benefits of influenza immunization pre- and
post-partum. Few U.S. mothers breastfeed as long as 6 months
[29], but the possibility of long-term protection of the infant from
influenza should be considered in discussions with breastfeeding
mothers.
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